Ticker
ACHL

Price
1.75
Stock movement up
+- (%)
Company name
Achilles Therapeutics PLC ADR
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
71.35M
Ent verdi
-139.85M
Pris/omsetning
-
Pris/bok
0.27
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-64.21%
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2022-12-05

UTBYTTE

ACHL betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok0.27
EV i forhold til salg-

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall40.77M
EPS (TTM)-1.59
FCF per aksje (TTM)-0.91

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsinntekter (TTM)-69.46M
Netto inntekt (TTM)-64.69M
EPS (TTM)-1.59
EPS (1 år fremover)-2.09

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenestemargin (TTM)-

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter236.93M
Netto fordringer14.46M
Samlede omløpsmidler259.05M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler292.19M
Leverandørgjeld4.04M
Kortsiktig/nåværende langsiktig gjeld11.88M
Sum kortsiktig gjeld17.85M
Sum gjeld25.73M
Aksjonærenes egenkapital266.45M
Netto varige driftsmidler266.45M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-32.96M
Kapitalutgifter (TTM)4.04M
Fri kontantstrøm (TTM)-37.00M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-24.28%
Avkastning på eiendeler-22.14%
Avkastning på investert kapital-24.28%
Kontantavkastning på investert kapital-13.89%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning1.87
Daglig høy1.87
Daglig lav1.71
Daglig volum30K
Tidenes høyeste17.86
1 år analytikerestimat14.33
Beta-
EPS (TTM)-1.59
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon27 Feb 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ACHLS&P500
Nåværende prisfall fra toppnotering-90.20%-14.82%
Høyeste prisfall-91.10%-56.47%
Dato for høyeste fall9 Nov 20229 Mar 2009
Gj.snittlig fall fra topp-69.47%-11.46%
Gj.snittlig tid til ny topp212 days13 days
Maks tid til ny topp421 days1805 days
SELSKAPSOPPLYSNINGER
ACHL (Achilles Therapeutics PLC ADR) company logo
Markedsverdi
71.35M
Markedsverdi kategori
Small-cap
Beskrivelse
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Ansatte
242
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results s...
30. november 2022
- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches -LONDON, Nov. ...
22. november 2022
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
13. november 2022
- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 - - Strong cash balance of $179.9...
8. november 2022
Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the ...
1. november 2022
Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets Virtual Roundtable to...
6. oktober 2022
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
7. september 2022
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplasti...
31. august 2022
Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.
26. august 2022
The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.
25. august 2022
Neste side